<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2016//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_160101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">27528392</PMID>
        <DateCreated>
            <Year>2016</Year>
            <Month>8</Month>
            <Day>16</Day>
        </DateCreated>
        <DateRevised>
            <Year>2016</Year>
            <Month>8</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-904X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Aug</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmaceutical research</Title>
                <ISOAbbreviation>Pharm. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The ability of human melanotransferrin (hMTf) to carry a therapeutic concentration of trastuzumab (BTA) in the brain after conjugation (in the form of trastuzumab-melanotransferrin conjugate, BT2111 conjugate) was investigated by measuring the reduction of the number and size of metastatic human HER(2+) breast cancer tumors in a preclinical model of brain metastases of breast cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Human metastatic brain seeking breast cancer cells were injected in NuNu mice (n?=?6-12 per group) which then developed experimental brain metastases. Drug uptake was analyzed in relation to metastasis size and blood-tumor barrier permeability. To investigate in-vivo activity against brain metastases, equimolar doses of the conjugate, and relevant controls (hMTf and BTA) in separate groups were administered biweekly after intracardiac injection of the metastatic cancer cells.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The trastuzumab-melanotransferrin conjugate (BT2111) reduced the number of preclinical human HER(2+) breast cancer metastases in the brain by 68% compared to control groups. Tumors which remained after treatment were 46% smaller than the control groups. In contrast, BTA alone had no effect on reducing number of metastases, and was associated with only a minimal reduction in metastasis size.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results suggest the novel trastuzumab-melanotransferrin conjugate (BT2111) may have utility in treating brain metastasis and validate hMTf as a potential vector for antibody transport across the Blood Brain Barrier (BBB).</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Nounou</LastName>
                    <ForeName>Mohamed Ismail</ForeName>
                    <Initials>MI</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutics, School of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences, Appalachian College of Pharmacy, Oakwood, Virginia, 24631, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Adkins</LastName>
                    <ForeName>Chris E</ForeName>
                    <Initials>CE</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, West Virginia University Health Sciences Center, Morgantown, West Virginia, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Rubinchik</LastName>
                    <ForeName>Evelina</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>biOasis Technologies Inc., Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Terrell-Hall</LastName>
                    <ForeName>Tori B</ForeName>
                    <Initials>TB</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, West Virginia University Health Sciences Center, Morgantown, West Virginia, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Afroz</LastName>
                    <ForeName>Mohamed</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, West Virginia University Health Sciences Center, Morgantown, West Virginia, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Vitalis</LastName>
                    <ForeName>Tim</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>biOasis Technologies Inc., Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Gabathuler</LastName>
                    <ForeName>Reinhard</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>biOasis Technologies Inc., Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Tian</LastName>
                    <ForeName>Mei Mei</ForeName>
                    <Initials>MM</Initials>
                    <AffiliationInfo>
                        <Affiliation>biOasis Technologies Inc., Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Lockman</LastName>
                    <ForeName>Paul R</ForeName>
                    <Initials>PR</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, West Virginia University Health Sciences Center, Morgantown, West Virginia, USA. prlockman@hsc.wvu.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType UI="">JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Pharm Res</MedlineTA>
            <NlmUniqueID>8406521</NlmUniqueID>
            <ISSNLinking>0724-8741</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">antibody trastuzumab-melanotransferrin conjugate (BT2111)</Keyword>
            <Keyword MajorTopicYN="N">blood brain barrier (BBB)</Keyword>
            <Keyword MajorTopicYN="N">brain metastases</Keyword>
            <Keyword MajorTopicYN="N">human melanotransferrin (hMTf)</Keyword>
            <Keyword MajorTopicYN="N">metastatic HER2+ breast cancer tumors</Keyword>
            <Keyword MajorTopicYN="N">trastuzumab (BTA)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11095-016-2015-0</ArticleId>
            <ArticleId IdType="pii">10.1007/s11095-016-2015-0</ArticleId>
            <ArticleId IdType="pubmed">27528392</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
